LUGPA CME Program
Disruptive Technologies: What to Know?
November 1, 2018
12:45 p.m. – 5:10 p.m.
Fairmont Chicago, Millennium Park
The field of GU Oncology has been developing with exceptional rapidity as evidenced by the multitude of FDA approved diagnostic, imaging and therapeutics for both oncologic and non-oncologic management of prostate and bladder disease. Concomitantly, urology practices are recognizing the importance of providing state-of-the-art care for these patients which can involve both multidisciplinary care as well as maintaining their existing expertise and strengthening their clinics of excellence. Challenges involve providing ongoing education to address not only the most recently presented/published trial data but also how to best understand and optimize diagnosis, evaluation, therapeutic selection and patient management. Hence, the course will address these issues specifically focusing on the newer disruptive technologies which may change current practice patterns for GU patients with both malignant and non-malignant conditions.
At the conclusion of the LUGPA 2018 CME Course, attendees will be able to:
- Review the differences in genetic testing for prostate cancer patients: germline vs somatic…how is the testing performed, who should be tested, and how to create a pathway for patient counseling and develop a pathway for optimal testing.
- Review the importance of family history assessment for all urology patients who may have a hereditable risk for cancer.
- Review the appropriate indications and techniques for optimal prostate and bladder patient biopsies.
- Review the most recent understanding of both day and nighttime voiding dysfunction and how the accurate evaluation will influence therapeutic decision making as well as interventional options.
- Explain the ongoing clinical advanced prostate cancer trials and why they may affect combination and sequencing strategies.
- Identify the adverse event and toxicity profile in order to best establish specialists within your GU Oncology clinic for the use of immune-oncologic agents.
- Review intravesical bladder cancer therapies: how to maximize current approved treatments according to recent AUA guideline updates, and be cognizant of the plethora of high risk non-muscle invasive bladder cancer clinical trial options (vaccines/immunotherapies) which will potentially answer this unmet need.
- Describe the rapidly evolving field of diagnostic imaging and the value proposition of the different imaging modalities, both older and newer, and when to order which diagnostic test.